The UHRF family

Oncogenes that are drugable targets for cancer therapy in the near future?

Christian Bronner, Mayada Achour, Yoshimi Arima, Thierry Chataigneau, Hideyuki Saya, Valérie B. Schini-Kerth

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

In this paper, we review the current literature about the UHRF family that in particular includes the UHRF1 and UHRF2 genes. Its members play a fundamental role in cell proliferation through different structural domains. These domains include a ubiquitin-like domain (NIRF_N), a plant homeodomain (PHD) domain, a SRA domain and a RING domain. The SRA domain has only been observed in this family probably conferring unique properties to it. The unique enzymatic activity so far identified in this family involves the RING finger that contains a ubiquitin E3 ligase activity toward, for instance, histones. The physiological roles played by the UHRF family are most likely exerted during embryogenic development and when proliferation is required in adults. Interestingly, UHRF members are putative oncogenes regulated by tumor suppressor genes, but they exert also a feedback control on these latter. Finally, we propose some new roles for this family, including regulation and/or inheritance of the epigenetic code. Alteration of these regulatory mechanisms, such as those occurring in cancer cells, may be involved in carcinogenesis. The reasons why the UHRF family could be an interesting target for developing anticancer drugs is also developed.

Original languageEnglish
Pages (from-to)419-434
Number of pages16
JournalPharmacology and Therapeutics
Volume115
Issue number3
DOIs
Publication statusPublished - 2007 Sep
Externally publishedYes

Fingerprint

Ubiquitin-Protein Ligases
Ubiquitin
Tumor Suppressor Genes
Oncogenes
Epigenomics
Histones
Carcinogenesis
Cell Proliferation
Pharmaceutical Preparations
Genes
Neoplasms
Therapeutics

Keywords

  • Cancer
  • E3 ligases
  • ICBP90
  • Np95
  • Oncogenes
  • UHRF

ASJC Scopus subject areas

  • Pharmacology

Cite this

The UHRF family : Oncogenes that are drugable targets for cancer therapy in the near future? / Bronner, Christian; Achour, Mayada; Arima, Yoshimi; Chataigneau, Thierry; Saya, Hideyuki; Schini-Kerth, Valérie B.

In: Pharmacology and Therapeutics, Vol. 115, No. 3, 09.2007, p. 419-434.

Research output: Contribution to journalArticle

Bronner, Christian ; Achour, Mayada ; Arima, Yoshimi ; Chataigneau, Thierry ; Saya, Hideyuki ; Schini-Kerth, Valérie B. / The UHRF family : Oncogenes that are drugable targets for cancer therapy in the near future?. In: Pharmacology and Therapeutics. 2007 ; Vol. 115, No. 3. pp. 419-434.
@article{b39103afa39245f9963731b40f3411a1,
title = "The UHRF family: Oncogenes that are drugable targets for cancer therapy in the near future?",
abstract = "In this paper, we review the current literature about the UHRF family that in particular includes the UHRF1 and UHRF2 genes. Its members play a fundamental role in cell proliferation through different structural domains. These domains include a ubiquitin-like domain (NIRF_N), a plant homeodomain (PHD) domain, a SRA domain and a RING domain. The SRA domain has only been observed in this family probably conferring unique properties to it. The unique enzymatic activity so far identified in this family involves the RING finger that contains a ubiquitin E3 ligase activity toward, for instance, histones. The physiological roles played by the UHRF family are most likely exerted during embryogenic development and when proliferation is required in adults. Interestingly, UHRF members are putative oncogenes regulated by tumor suppressor genes, but they exert also a feedback control on these latter. Finally, we propose some new roles for this family, including regulation and/or inheritance of the epigenetic code. Alteration of these regulatory mechanisms, such as those occurring in cancer cells, may be involved in carcinogenesis. The reasons why the UHRF family could be an interesting target for developing anticancer drugs is also developed.",
keywords = "Cancer, E3 ligases, ICBP90, Np95, Oncogenes, UHRF",
author = "Christian Bronner and Mayada Achour and Yoshimi Arima and Thierry Chataigneau and Hideyuki Saya and Schini-Kerth, {Val{\'e}rie B.}",
year = "2007",
month = "9",
doi = "10.1016/j.pharmthera.2007.06.003",
language = "English",
volume = "115",
pages = "419--434",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - The UHRF family

T2 - Oncogenes that are drugable targets for cancer therapy in the near future?

AU - Bronner, Christian

AU - Achour, Mayada

AU - Arima, Yoshimi

AU - Chataigneau, Thierry

AU - Saya, Hideyuki

AU - Schini-Kerth, Valérie B.

PY - 2007/9

Y1 - 2007/9

N2 - In this paper, we review the current literature about the UHRF family that in particular includes the UHRF1 and UHRF2 genes. Its members play a fundamental role in cell proliferation through different structural domains. These domains include a ubiquitin-like domain (NIRF_N), a plant homeodomain (PHD) domain, a SRA domain and a RING domain. The SRA domain has only been observed in this family probably conferring unique properties to it. The unique enzymatic activity so far identified in this family involves the RING finger that contains a ubiquitin E3 ligase activity toward, for instance, histones. The physiological roles played by the UHRF family are most likely exerted during embryogenic development and when proliferation is required in adults. Interestingly, UHRF members are putative oncogenes regulated by tumor suppressor genes, but they exert also a feedback control on these latter. Finally, we propose some new roles for this family, including regulation and/or inheritance of the epigenetic code. Alteration of these regulatory mechanisms, such as those occurring in cancer cells, may be involved in carcinogenesis. The reasons why the UHRF family could be an interesting target for developing anticancer drugs is also developed.

AB - In this paper, we review the current literature about the UHRF family that in particular includes the UHRF1 and UHRF2 genes. Its members play a fundamental role in cell proliferation through different structural domains. These domains include a ubiquitin-like domain (NIRF_N), a plant homeodomain (PHD) domain, a SRA domain and a RING domain. The SRA domain has only been observed in this family probably conferring unique properties to it. The unique enzymatic activity so far identified in this family involves the RING finger that contains a ubiquitin E3 ligase activity toward, for instance, histones. The physiological roles played by the UHRF family are most likely exerted during embryogenic development and when proliferation is required in adults. Interestingly, UHRF members are putative oncogenes regulated by tumor suppressor genes, but they exert also a feedback control on these latter. Finally, we propose some new roles for this family, including regulation and/or inheritance of the epigenetic code. Alteration of these regulatory mechanisms, such as those occurring in cancer cells, may be involved in carcinogenesis. The reasons why the UHRF family could be an interesting target for developing anticancer drugs is also developed.

KW - Cancer

KW - E3 ligases

KW - ICBP90

KW - Np95

KW - Oncogenes

KW - UHRF

UR - http://www.scopus.com/inward/record.url?scp=34548451241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548451241&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2007.06.003

DO - 10.1016/j.pharmthera.2007.06.003

M3 - Article

VL - 115

SP - 419

EP - 434

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

IS - 3

ER -